Cixutumumab
Cixutumumab Basic information
- Product Name:
- Cixutumumab
- Synonyms:
-
- Cixutumumab
- Research Grade Cixutumumab(DHC29904)
- Research Grade Cixutumumab
- Cixutumumab (anti-IGF1R)
- CAS:
- 947687-12-9
- MW:
- 0
- Mol File:
- Mol File
Cixutumumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Cixutumumab Usage And Synthesis
Uses
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer[1].
in vivo
Cixutumumab (IMC-A12) (1 mg/rat; i.p.; twice weekly for 6 weeks) shows broad-spectrum antitumor activity, inhibits tumor growth of the PPTP’s in vivo solid tumor panels[1].
| Animal Model: | CB17SC-M scid-/- female mice (solid tumor xenografts model)[1]. |
| Dosage: | 1 mg/rat |
| Administration: | Intraperitoneal injection; twice weekly for 6 weeks. |
| Result: | Demonstrated broad antitumor activity against the PPTP’s in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression. |
References
[1] Houghton PJ, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6. DOI:10.1002/pbc.22367
CixutumumabSupplier
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com